Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
-0.75 (-0.42%)
Real-time:   12:55PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 175.31 - 177.82
52 week 147.60 - 270.63
Open 175.99
Vol / Avg. 972,333.00/2.45M
Mkt cap 33.75B
P/E 26.34
Div/yield 0.66/0.77
EPS 6.75
Shares 610.30M
Beta 1.05
Inst. own 7%
Jul 27, 2016
Q2 2016 Shire PLC Earnings Release Add to calendar
May 27, 2016
Shire PLC Ordinary Shareholders Meeting - 3:00AM EDT - Add to calendar
May 4, 2016
Shire PLC at Deutsche Bank Health Care Conference
Apr 29, 2016
Q1 2016 Shire PLC Earnings Call
Apr 29, 2016
Q1 2016 Shire PLC Earnings Release
Apr 28, 2016
Shire PLC Annual Shareholders Meeting
Apr 27, 2016
Shire PLC Annual Shareholders Meeting (Estimated)
Mar 8, 2016
Shire PLC at Cowen Health Care Conference - Webcast
Mar 1, 2016
Shire PLC at Credit Suisse One-on-One Healthcare Conference
Feb 11, 2016
Full Year 2015 Shire PLC Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 23.96% 20.88%
Operating margin 31.82% 22.12%
EBITD margin - 44.15%
Return on average assets 8.08% 8.86%
Return on average equity 16.32% 14.47%
Employees 5,548 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus, Dubl
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal (GI), and focuses its early development projects primarily on rare diseases. Its products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, ADDERALL XR, INTUNIV, LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 52
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 55
Bio & Compensation  - Reuters
Oliver Strawbridge Senior Assistant Company Secretary
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 56
Bio & Compensation  - Reuters
Gail D. Fosler Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 60
Bio & Compensation  - Reuters